Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
08:00am, Tuesday, 05'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for AR
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
07:30am, Monday, 04'th May 2026
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the events in which it is scheduled to participate throughout the month of May, 2026.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasir
B. Metzler seel. Sohn & Co. AG Takes $1.37 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR
03:46am, Monday, 27'th Apr 2026
B. Metzler seel. Sohn and Co. AG purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exch
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHM
Farther Finance Advisors LLC Purchases 11,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
03:44am, Friday, 24'th Apr 2026
Farther Finance Advisors LLC grew its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 2,923.0% in the fourth quarter, according to the company in its most recent 13F filing wit
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
02:38am, Monday, 06'th Apr 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbea
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of
Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead
07:13am, Thursday, 26'th Mar 2026
Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial stage, with its first approval for plozasiran in FCS. ARWR's valuation reflects a 5% downside, 10-15% base case upside, an
Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead
05:02am, Tuesday, 10'th Mar 2026
Arrowhead Pharmaceuticals (NASDAQ: ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.
03:40am, Monday, 09'th Mar 2026
Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 63.4% during the undefined quarter, according to its most recent filing with the Securities and Exc
GSK Strikes $1 Billion China RNA Deal
11:43am, Tuesday, 24'th Feb 2026
GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
07:30am, Tuesday, 24'th Feb 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual H
China Universal Asset Management Co. Ltd. Acquires 14,497 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
04:18am, Saturday, 21'st Feb 2026
China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 52.3% during the third quarter, according to its most recent filing with th
Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
03:21am, Friday, 20'th Feb 2026
Rhumbline Advisers increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 3.1% during the undefined quarter, according to its most recent Form 13F filing with the Securitie
